Comparison of treatment with habitual dose of lovastatin and bezafibrate on post heart transplantation hyperlipidemia;Comparacion del tratamiento con bezafibrato y lovastatina a dosis habituales en la hiperlipemia postrasplante cardiaco

Revista Espanola de Cardiologia

Volumn 49, Issue 12, 1996, Pages 892-898

  Zambrana Garcí, José L ^a   Lopez Miranda, José ^a   Anguita Sánchez, Manuel ^a   Blanco Cerrada, Julia ^a   Vallés Belsúe, Federico ^a   Mediavilla, Jaime Casares ^a   Carvajal, Ignacio Muñoz ^a   Jiménez Perepérez, José A ^a   Pérez Jiménez, Francisco ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

bezafibrate; heart transplantation; hyperlipidemia; lovastatin

Indexed keywords

BEZAFIBRATE; MEVINOLIN; ANTILIPEMIC AGENT; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIET; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BEZAFIBRATE; CROSS-OVER STUDIES; FEMALE; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 0030332755     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bieber CP, Hunt SA, Schwinn DA, Jamieson SA, Reitz BA, Oyer PE et al. Complications in long-term survivors of cardiac trasplantation. Transplant Proc 1981; 8: 207-211.
2. Keogh AM, Valantine HA, Hunt SA, Schroeder JS, McIntosh N, Oyer PE et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 1992; 11: 892-901.
3. Demetris AJ, Zerbe T, Banner B. Morphology of solid organ allograft arteriopathy: identification of proliferating intimai cell populations. Transplant Proc 1989; 21: 2.667-3.669.
4. Hess ML, Hastillo A, Mohanakumar T, Rabin B, Lee A, Griffith BP et al. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983; 68 (Supl 2): 94-101.
5. Miller LW. Long-term complications of cardiac transplantation. Prog Cardiovasc Dis 1991; 33: 229-282.
6. Stamler JS, Vaughan DE, Rudd MA, Mudge GH, Kirshenbaum J, Young P et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988; 62: 1.268-1.272.
7. Eich D, Thompson JA, Ko D, Hastillo A, Lower R, Katz M et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991; 10: 45-49.
8. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Paytonross C et al. Hyperlipemia after heart transplantation: report of a 6-year experience with treatment recommendation. J Am Coll Cardiol 1992; 19: 1.315-1.321.
9. Zambrana JL, Hidalgo L, Anguita M, Concha M, Blanco J, Jiménez Perepérez JA et al. Relación de la hiperlipemia postrasplante cardíaco con el tipo de cardiopatía que motivó la intervención. Clin Invest Arteriosclerosis 1994; 6: 176-180.
10. Salen P, Lorgeril M, Boissoanat P, Monjaud I, Guidollet J, Dureau G et al. Effects of a French Mediterranean diet on heart transplant recipients with hypercholesterolemia. Am J Cardiol 1994; 73: 825-827.
11. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33.
12. Vessby B, Lithell H, Hellsing K, Östlund-Lindqvist A-M, Gustaffson I-B, Boberg J et al. Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. Atherosclerosis 1980; 37: 257-269.
13. Hidalgo L, Zambrana JL, Blanco A, López-Granados A, Concha M, Casares J et al. Lovastatin versus Bezafibrate for post heart transplantation hyperlipidemia treatment. J Heart Lung Transplant 1995; 14: 461-467.
14. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148: 36-39.
15. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-156.
16. Lipid Research Clinics Program. The lipid Research Clinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
17. Bertomeu A, Zambón D, Bedini JL, Sanllehy C, Casals E, Ros E. Eficacia comparativa del tratamiento hipolipemiante con lovastatina y bezafibrato en pacientes con hipercolesterolemia primaria. Clin Invest Arteriosclerosis 1990; 2: 136-145.
18. Beil FU, Schrameyer-Wernecke A, Beisiegel U, Greten H, Karkas JD, Liou R et al. Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate. Cardiology 1990; 77 (Supl 4): 22-32.
19. Sánchez Domínguez J, Rodríguez Padial L, Navarro A, Barcina C, Fernández E, Rivera G et al. Tratamiento comparativo de la hipercolesterolemia primaria con lovastatina y bezafibrato. Ensayo aleatorizado y a doble ciego. Rev Esp Cardiol 1991; 44: 251-257.
20. Schumacher M, Eber B, Silberbauer K, Breier C, Stuhlinger W, Schmidt P et al. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia. Acta Med Austriaca 1992; 19: 140-144.
21. Sinzinger H, Pirich C, Kondor P, Etti H. Atherogenic risk reduction in patients with dyslipidaemia. Comparison between bezafibrate and lovastatin. Eur Heart J 1995; 16: 1.491-1.501.
22. Hidalgo L, López-Miranda J, Espino A, Alcalá J, Blanco J, Prada JL et al. The effect of Lovastatin and Bezafibrate on cyclosporin induced hyperlipidemia in rabbits. Transpl Proc 1995; 27: 1.857-1.861.
23. Kuo PC, Kirshenbaum JM, Gordon J, Laffel G, Young P, DiSesa VJ et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989; 64: 631-635.
24. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82 (Supl 4): 281-283.
25. Anguita M, Alonso-Pulpón L, Arizón JM, Cavero MA, Vallés F, Segovia J et al. Comparison of the effectiveness of Lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery disease. Am J Cardiol 1994; 74: 776-779.
26. Pérez-Jiménez F, Hidalgo L, Zambrana JL, Arizón JM, Jiménez-Perepérez JA, Concha M et al. Comarison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients. Am J Cardiol 1995; 75: 648-650.
27. Peters JR, Kubo SH, Olivari MT, Knutson KR, Hunninghake DB. Treatment of hiperlipemia in heart transplant recipients with gemfibrozil ± lovastatin. Am J Cardiol 1993; 71: 1.485-1.488.
28. Prager R, Schernmthaner G, Kostner GM, Mühlhauser I, Zechner R. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics. Atherosclerosis 1982; 43: 321-327.
29. Monk JP, Todd PA. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic uase in hyperlipidemia. Drugs 1987; 33: 539-576.
30. Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine in the therapy of severe primary hypercholesterolaemia. JAMA 1988; 260: 359-366.
31. Hunninghake DB, Miller VT, Palmer RH. Therapeutic response to lovastatin in nonfamilial hypercholesterolemia. JAMA 1986; 256: 2.829-2.832.
32. Schulzeck P, Bojanovski M, Jochim A, Canzler H, Bojanovski D. Comparison between smivastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet 1988; 19: 611-612.
33. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987; 83 (Supl 5B): 9-20.
34. Tikkanen MJ. Fibric acid derivates. Curr Opin Lipidol 1992; 3: 29-33.
35. Gurecki J, Warty V, Sanghvi A. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc 1985; 17 (Supl 4): 1.997-2.002.
36. Awni WM, Heim-Duthoy K, Kasike BL. Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients. Transplant Proc 1990; 22: 1.193-1.196.
37. McKenney JM. Lovastatin: a new cholesterol-lowering agent. Clin Invest 1988; 7: 21-36.
38. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolisis and acute renal failure in a heart transplant recipient receiving lovastatin. N Engl J Med 1988; 318: 46-47.
39. East C, Alivizatos PA, Grundy SM, Jones PH, Fanner JA. Rhabdomyolisis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 47-48.
40. Carrier M, Pelletier GB, Genest J, Cartier R, Leclerc Y, Pelletier LC. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. Ann Thorac Surg 1994; 57: 353-356.
41. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang X-M et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.